Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Corey J Langer

Showing results (131-140 of 225) with videos related to

Pageof 23
Sort By:
Clinical Lung Cancer|November 21, 2017
The Role of Advanced Imaging in Assessing Response to Definitive Chemoradiation Before Prophylactic Cranial Irradiation in Limited-Stage Small-Cell Lung CancerAparna H Kesarwala, Diana J Lu, Eric Xanthopoulos, et al.
Journal of Thoracic Disease|March 31, 2018
A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapyMatthew A Gubens, Jody C Chuang, Wallace Akerley, et al.
Frontiers in Oncology|February 12, 2021
<i>nab</i>-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled AnalysisCorey J Langer, Ajeet Gajra, Cesare Gridelli, et al.
International Journal of Radiation Oncology, Biology, Physics|September 4, 2010
ACR Appropriateness Criteria® on Induction and Adjuvant Therapy for Stage N2 Non-Small-Cell Lung Cancer: expert panel on radiation oncology-lungRamesh S Gopal, Sarita Dubey, Kenneth E Rosenzweig, et al.
Clinical Lung Cancer|April 8, 2022
Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and PemetrexedChristine A Ciunci, Jacob B Reibel, Tracey L Evans, et al.
Head & Neck|February 19, 2005
Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studiesNoel M Kramer, Eric M Horwitz, Jonathan Cheng, et al.
Journal of the National Cancer Institute|September 10, 2011
Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410Walter J Curran, Rebecca Paulus, Corey J Langer, et al.
BMC Cancer|October 12, 2021
Impact of telemedicine adoption on accessibility and time to treatment in patients with thoracic malignancies during the COVID-19 pandemicVivek Nimgaonkar, Charu Aggarwal, Abigail T Berman, et al.
JAMA Oncology|July 12, 2019
Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 TrialJoshua M Bauml, Rosemarie Mick, Christine Ciunci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124Primo N Lara, Ronald Natale, John Crowley, et al.
Pageof 23

Showing results (131-140 of 225) with videos related to

Sort By:
Pageof 23
Clinical Lung Cancer|November 21, 2017
The Role of Advanced Imaging in Assessing Response to Definitive Chemoradiation Before Prophylactic Cranial Irradiation in Limited-Stage Small-Cell Lung CancerAparna H Kesarwala, Diana J Lu, Eric Xanthopoulos, et al.
Journal of Thoracic Disease|March 31, 2018
A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapyMatthew A Gubens, Jody C Chuang, Wallace Akerley, et al.
Frontiers in Oncology|February 12, 2021
<i>nab</i>-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled AnalysisCorey J Langer, Ajeet Gajra, Cesare Gridelli, et al.
International Journal of Radiation Oncology, Biology, Physics|September 4, 2010
ACR Appropriateness Criteria® on Induction and Adjuvant Therapy for Stage N2 Non-Small-Cell Lung Cancer: expert panel on radiation oncology-lungRamesh S Gopal, Sarita Dubey, Kenneth E Rosenzweig, et al.
Clinical Lung Cancer|April 8, 2022
Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and PemetrexedChristine A Ciunci, Jacob B Reibel, Tracey L Evans, et al.
Head & Neck|February 19, 2005
Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studiesNoel M Kramer, Eric M Horwitz, Jonathan Cheng, et al.
Journal of the National Cancer Institute|September 10, 2011
Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410Walter J Curran, Rebecca Paulus, Corey J Langer, et al.
BMC Cancer|October 12, 2021
Impact of telemedicine adoption on accessibility and time to treatment in patients with thoracic malignancies during the COVID-19 pandemicVivek Nimgaonkar, Charu Aggarwal, Abigail T Berman, et al.
JAMA Oncology|July 12, 2019
Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 TrialJoshua M Bauml, Rosemarie Mick, Christine Ciunci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124Primo N Lara, Ronald Natale, John Crowley, et al.
Pageof 23